or Try an Advanced Search...

    Technical Analysis for PHAT - Phathom Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 6.96 -0.43% -0.03
    PHAT closed up 2.95 percent on Wednesday, January 22, 2025, on 63 percent of normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Flat
    Historical PHAT trend table...
    Date Alert Name Type % Chg
    Bullish Engulfing Bullish -0.43%
    Hammer Candlestick Bullish 2.50%
    Lower Bollinger Band Touch Weakness 2.50%
    1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Older End-of-Day Signals for PHAT ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 2 hours ago
    Down 3% about 2 hours ago
    Fell Below Previous Day's Low about 2 hours ago
    60 Minute Opening Range Breakdown about 3 hours ago
    Down 2 % about 3 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    PHAT Chart by TradingView

    Profile

    Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Life Sciences Acid Natural Sciences Medication Gastrointestinal Disorders Potassium Gastrointestinal Disease Tadataka Yamada

    Is PHAT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jan 19 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic?
    Dec 12 Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?
    Dec 11 Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable
    Dec 11 Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
    Dec 6 Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround
    Nov 19 Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know
    Nov 10 Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript
    Nov 8 Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
    Nov 7 Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
    Nov 7 Phathom Pharmaceuticals GAAP EPS of -$1.32 beats by $0.21, revenue of $16.4M beats by $3.99M
    See more PHAT news...

    Comments

    Indicators

    Indicator Value
    52 Week High 19.71
    52 Week Low 6.065
    Average Volume 1,367,228
    200-Day Moving Average 11.93
    50-Day Moving Average 8.66
    20-Day Moving Average 7.35
    10-Day Moving Average 6.93
    Average True Range 0.56
    RSI (14) 38.65
    ADX 35.96
    +DI 13.19
    -DI 27.99
    Chandelier Exit (Long, 3 ATRs) 6.92
    Chandelier Exit (Short, 3 ATRs) 8.03
    Upper Bollinger Bands 8.31
    Lower Bollinger Band 6.39
    Percent B (%b) 0.31
    BandWidth 26.05
    MACD Line -0.60
    MACD Signal Line -0.70
    MACD Histogram 0.0943
    Fundamentals Value
    Market Cap 477.96 Million
    Num Shares 68.4 Million
    EPS -5.74
    Price-to-Earnings (P/E) Ratio -1.22
    Price-to-Sales 18.12
    Price-to-Book 25.37
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.46
    Resistance 3 (R3) 7.44 7.27 7.38
    Resistance 2 (R2) 7.27 7.15 7.28 7.35
    Resistance 1 (R1) 7.13 7.08 7.20 7.15 7.33
    Pivot Point 6.96 6.96 7.00 6.97 6.96
    Support 1 (S1) 6.82 6.84 6.89 6.84 6.65
    Support 2 (S2) 6.65 6.77 6.66 6.63
    Support 3 (S3) 6.51 6.65 6.60
    Support 4 (S4) 6.53